Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the differences between KB solution and PG + Ethanol solution for RU58841 in treating hair loss. It compares the effectiveness and properties of these two solutions.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

The conversation is about someone planning to start finasteride for hair loss and wanting to interpret pre-treatment blood panels to assess the risk of side effects like gynecomastia. They list various tests to measure hormone levels and other health indicators.

User considers trying AAPE for hair restoration, costing $700 for 6 months. Others discuss its potential effectiveness and mention a study with promising results.

PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.

The user is concerned about high prolactin levels and low testosterone levels after stopping finasteride for three weeks. They are considering resuming finasteride but are worried it might further increase prolactin levels.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. Users seek Alfatradiol sources and share personal experiences.

Vitamins and minerals like vitamin E, zinc, and iron may aid hair growth, especially in cases of deficiency. Pumpkin seed oil, saw palmetto, horsetail, and AminoMar show some promise for improving hair health and count.

The conversation discusses a personalized hair loss treatment plan based on DNA test results, recommending Minoxidil, Dutasteride, 17-alpha Estradiol, Cetirizine, and PRP sessions. The test identifies a high risk of hair loss due to DHT but a good response to Minoxidil, suggesting a tailored approach to treatment.

The user is exploring hair loss treatments and is interested in procyanidin B2 and annurca apples but has concerns about the effectiveness and availability of supplements. They cannot use Dutasteride or Finasteride and are considering Minoxidil with microneedling.

The conversation provides a detailed list of blood tests recommended before starting finasteride to establish a baseline for monitoring potential side effects. A shorter list is also provided for those with limited funds, and the user shares personal experience of using finasteride without issues for about nine years.

Sons offers free Biotin capsules, Thickening Clay, or Conditioner to UK men for hair care testing. Interested individuals can apply online to receive these products.

Aminexil/Kopexil may help reduce hair loss by addressing perifollicular fibrosis in androgenetic alopecia, but it lacks the extensive clinical backing of finasteride and minoxidil. Some users find it effective, but availability and cost are issues, especially in the US where it's not FDA-approved.

An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.

The user is experiencing hair thinning and has a vitamin D deficiency, which they suspect might be causing the issue, but they are also considering androgenic alopecia (AGA) as a cause. They are currently using minoxidil and are unable to get finasteride prescribed, while others suggest addressing the vitamin D deficiency and consulting a dermatologist.

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

The post discusses the user's experience with hair loss treatment RU58841, which was tested for quality and found to be 96+% pure. The conversation includes various responses, with some users questioning the safety of the product and others expressing satisfaction with the test results.

A user increased their dutasteride dosage from 0.5mg to 1mg daily, resulting in a rise in DHT levels from 148 pg/mL to 281 pg/mL, and is considering switching back to finasteride due to continued hair loss. Replies suggest retesting and emphasize the importance of bloodwork before starting treatments.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

Choosing between KB and PG solutions for applying RU58841, considering factors like scalp oiliness and absorption. Some users prefer KB for being gentler, while others use PG and recommend washing hair before application for better results.

Elevated bile acids can inhibit the enzyme AKR1C2, leading to increased DHT levels, which may accelerate hair loss in those predisposed to androgenetic alopecia. Treatments mentioned include topical minoxidil and finasteride.

Oral minoxidil treatment increased hair density and shaft caliber in AGA patients. Side effects included hypertrichosis and lower extremity edema, with younger patients experiencing fewer side effects.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The user is using testosterone and finasteride to prevent hair loss and is considering adding Primobolan or Masteron, which are DHT-derivatives. They are seeking advice on their genetic risk for male pattern baldness and whether they can safely use these compounds without significant hair loss.

The conversation discusses microneedling for hair loss, with the original poster experiencing pinpoint bleeding after using needles of 1.25mm and 0.5mm, possibly due to adding GHK-Cu to their treatment regimen. They are inquiring if others bleed at similar depths.

A 16-year-old diagnosed with male pattern baldness (MPB) was prescribed hair vitamins, vitamin D, a non-ketoconazole shampoo, and redenysl + serum, with a suggestion for GFC or IHRF treatments. Some users recommended minoxidil, ketoconazole, and derma stamping, while others advised against certain treatments until the age of 18.

The conversation is about managing allopregnanolone deficiency caused by 5-alpha-reductase inhibitors like finasteride or dutasteride. Specific treatments discussed for hair loss include Minoxidil, finasteride, and RU58841.

In this conversation, 4990 discussed various treatments for hair loss, including oral minoxidil, PRP, transplan, Jak inhibitors, Dutasteride, Finasteride, Olumiant, Ketoconazole, RU58841, microneedling, baricitinib, and CCCA. They recommended scalp biopsies in unclear cases of DUPA, twice weekly to twice daily shampooing for topical minoxidil users, and two sessions spaced one month apart with follow up at month three to determine the effectiveness of PRP treatment.